AMERICAN JOURNAL OF PHARMTECH RESEARCH

Journal home page: http://www.ajptr.com/

An Emphasis on Ebola Virus

Supriya Rajendra More[*1], Priyanka Rajendra Kajale, Swati Gokul Talele, Ghanshyam Narayan Chaudhari

1. Sandip institute of pharmaceutical sciences p.o. mahiravani, trambak road, nashik 422213

ABSTRACT

Ebola virus is responsible for several major commotion of hemorrhagic fever which results in high mortality which creats elevation in great public threat. However, the structural similarity of Ebola virus glycoprotein (GP) to retrovirus envelops has been recently allotted.[6] The development of pseudo type recombinant retroviral particle that can be used to define the various aspects related to Ebola virus biology. There is no any particular treatment for Ebola virus syndrome but it can be prevented. The FDA has permitted two medications, Zmapp and a RNA interference medication called TKM-Ebola[18] to be utilized as a part of individuals tainted with Ebola under these projects amid the 2014 episode. This review article is emphasis on life cycle of Ebola, pathophysiology, sign & symptoms, test & diagnosis, risk factor, treatment & precautions.

Keywords: Ebola Virus, Marburg Virus, Vaccine, West Africa.

*Corresponding Author Email: supriya7070@gmail.com

Received 27July 2014, Accepted13 August2014

Please cite this article as: More SR *et al.*, An Emphasis on Ebola Virus. American Journal of PharmTech Research 2015.

INTRODUCTION

This is a genuine and typically lethal infection in people and non-human primates, for example, gorillas, The Ebola infection ailment (EVD) was long ago known as Ebola hemorrhagic fever (Ebola HF) monkeys, and chimpanzees[6]. Ebola is one of a few viral hemorrhagic fevers (VHF) that has been brought on by contamination with the class Ebolavirus infection of the Filoviridae crew[6]. Ebola is known to be a standout amongst the most irresistible sicknesses on the planet today, with a casualty rate of up to 90%. Infection spreads through immediate contact with body liquids, blood, and tissues of individuals and creatures that are tainted with the infection[17]. Soil grown foods bats Fruit are the estimated potential regular stores of the Ebola infection. In the African rainforest, the ebola infection spread to human when they took care of tainted gorillas, chimpanzees, monkeys, tree grown foods bats, porcupines, and timberland impala[6]. Ebolavirus and Marburgvirus diverged several thousand years ago.[13]

MATERIALS AND METHOD

Life cycle of ebola

EVD is brought about by four of five infections ordered in the class Ebolavirus, family Filoviridae and order Mononegavirales. The four disease causing infections are Bundibugyo infection (BDBV), Sudan infection (SUDV), Tai Forest infection (TAFV), and one called essentially, Ebola infection (EBOV, previously Zaire Ebola infection)[6]. Ebola infection is the sole part of the Zaire ebolavirus species, and the most hazardous of the known Ebola ailment bringing about infections, and in addition being in charge of the biggest number of outbreaks[8]. The fifth infection, Reston infection (RESTV), is not thought to be sickness creating in people. The five Ebola infections are nearly identified with the Marburg infection Pathophysiology. Endothelial cells, mononuclear phagocytes and hepatocytes are the main targets of infection. After infection, a secreted glycoprotein (sGP) known as the Ebola virus glycoprotein (GP) is synthesized[6]. Ebola replication overwhelms protein synthesis of infected cells and host immune defenses. The GP forms a trimeric complex, which binds the virus to the endothelial cells lining the interior surface of blood vessels. The sGP forms a dimeric protein that interferes with the signaling of neutrophils, a type of white blood cell, which allows the virus to evade the immune system by inhibiting early steps of neutrophil activation[11]. These white blood cells also serve as carriers to transport the virus throughout the entire body to places such as the lymph nodes, liver, lungs, and spleen. The presence of viral particles and cell damage resulting from budding causes the release of cytokines (to be specific, TNF-α, IL-6, IL-8, etc.), which are the signaling molecules for fever and

inflammation[11]. The cytopathic effect, from infection in the endothelial cells, results in a loss of vascular integrity. This loss in vascular integrity is furthered with synthesis of GP, which reduces specific integrins responsible for cell adhesion to the inter-cellular structure, and damage to the liver, which leads to coagulopathy.

Epidemiology

The disease typically occurs in outbreaks in tropical regions of Sub-Saharan Africa[1]. From 1976 (when it was first identified) through 2013, the World Health Organization reported 1,716 confirmed cases[1, 2]. The largest outbreak to date is the ongoing 2014 West Africa Ebola virus outbreak, which is affecting Guinea, Sierra Leone, Liberiaand Nigeria[2, 3, 4]. As of 13 August, 2,127 cases have been identified, with 1,145 deaths.[2]

1976

The initially recognized instance of Ebola was on 26 August 1976, in Yambuku[19], a little country town in Mongala District in northern main victimized person, and the list case for the infection, was town school director MabaloLokela, who had visited a zone close to the Central African Republic fringe along the Ebola waterway between 12–22 August[9]. On 8 September he died of what would become known as the Ebola infection types of the ebolavirus[20]. In this manner various different cases were accounted for, just about all fixated on the Yambuku mission clinic or having close contact with an alternate case[20]. 318 cases and 280 passings happened in the DRC. The Ebola episode was contained with the assistance of the World Health Organization and transport from the Congolese flying corps, by isolating villagers, sanitizing medicinal gear, and giving defensive dress. The infection in charge of the introductory episode, first thought to be Marburg infection was later recognized as another kind of infection identified with Marburg, and named after the close-by Ebola river. An alternate ebolavirus, the Sudan infection species, was likewise recognized that same year when an episode happened in Sudan, influencing 284 individuals and executing 151.[21]

1995 to 2013

The second real flare-up happened in 1995 in the Democratic Republic of Congo, influencing 315 and killing 254. The following real episode happened in Uganda in 2000, influencing 425 and slaughtering 224; for this situation the Sudan infection was discovered to be the ebola virus species in charge of the outbreak.[20] In 2003 there was a flare-up in the Republic of Congo that influenced 143 and executed 128, a demise rate of 90%, the biggest to date[23]. In August 2007, 103 individuals were tainted by a suspected hemorrhagic fever episode in the town of Kampungu, Democratic Republic of the Congo. The episode began after the funerals of two town boss, and 217 individuals

in four towns fell ill[22, 24, 25] the 2007 flare-up in the end influenced 264 people and brought about the deaths of 187[1]. On 30 November 2007, the Uganda Ministry of Health affirmed a flare-up of Ebola in the Bundibugyo District in Western Uganda. After affirmation of examples tried by the United States National Reference Laboratories and the Centers for Disease Control, the World Health Organization affirmed the vicinity of another types of Ebolavirus, which was likely named Bundibugyo[26]. The WHO reported 149 instances of this new strain and 37 of those led to deaths[1]. The WHO affirmed two little flare-ups in Uganda in 2012. The main episode influenced 7 individuals and brought about the demise of 4 and the second influenced 24, ensuing in the deaths of 17. The Sudan variation was in charge of both episodes[1]. On 17 August 2012, the Ministry of Health of the Democratic Republic of the Congo reported a flare-up of the Ebola-Bundibugyo variation[27] in the eastern district.[28, 29] Other than its revelation in 2007, this was the main time that this variation has been recognized as the ebolavirus in charge of an episode. The WHO uncovered that the infection had sickened 57 individuals and guaranteed 29 lives. The reasonable justification of the episode was corrupted bush meat chased by neighborhood villagers around the towns of Isiro and Viadana.[1, 30]

2014 outbreak

In March 2014, the World Health Organization (WHO) reported a major Ebola episode in Guinea, a western African country; it is the biggest ever recorded, and the initially recorded in the region[31] researchers followed the flare-up to a two-year old child who died on 6 December.[32] Starting 10 April 2014, WHO reported 157 suspected and affirmed cases in Guinea, 22 suspected cases in Liberia, and 8 suspected cases in Sierra Leone[33, 34]. By 2014-07-31, they reported that the loss of life had arrived at 826 individuals from 1440 cases[35]. On 8 August, the WHO pronounced the plague to be an universal open wellbeing crisis. Urging the world to offer support to the influenced areas, the Director-General said, "Nations influenced to date essentially don't have the ability to deal with an episode of this size and many-sided quality on their own. I urge the worldwide group to give this backing on the most critical premise conceivable[36, 37]. Further endeavors to contain the flare-up were authorized by setting troops on streets to cordon off the tainted zones and stop the individuals who may be infected from leaving and further spreading the infection[38]. By mid-August 2014, 2,127 suspected cases including 1,145 passings had been accounted for, however the World Health Organization has said that these numbers may be limitlessly underestimated[21]. By mid-August, Doctors without Borders reported the circumstances in Liberia's state house Monrovia as "cataclysmic" and "breaking down every day". They report that apprehensions of Ebola among staff parts and patients has closed down a great part of the city's wellbeing framework which has

brought about leaving numerous individuals without treatment for different conditions[39]. On 16 August 2014, a quarantine center in West Point, Monrovia was attacked by protesters who distrust the government and health care workers and believe that the epidemic is a hoax. The attack caused a number of patients being monitored for Ebola to flee, while blood-soaked bedding and other infected items were removed. The incident was seen by medical officials as a disaster as it had the potential to accelerate the spread of the disease[40]. Tens of thousands of people in Liberia, Guinea, and Sierra Leone have been under quarantine, leaving them without access to food. The United Nations' World Food Programme has announced that it will deliver rations to 24,000 Liberian people affected by the epidemic[39]

Signs & Symptoms

Signs and manifestations of Ebola typically start all of a sudden with a flu like stage portrayed by exhaustion, fever, migraines, joint, muscle and stomach pain[6, 7]vomiting, looseness of the bowels and loss of appetite are likewise basic[10]. Less basic indications incorporate the accompanying: sore throat, chest pain, hiccups, shortness of breath and inconvenience swallowing[7, 14]. The normal time between getting the disease and the begin of indications (incubation period) is 8 to 10 days, yet it can fluctuate somewhere around 2 and 21 days[7, 8]. Skin appearances may incorporate a maculopapular rash (in around half of cases). Early indications of EVD may be like those of intestinal sickness, dengue fever or other tropical fevers, before the disease advances to the bleeding stage[6]. In 40–50% of cases, bleeding from puncture sites and mucous layers (e.g. gastrointestinal tract, nose, vagina and gums) has been reported[5]. In the bleeding stage, which regularly begins 5 to 7 days after first side effects[9] interior and subcutaneous bleeding may introduce itself through reddening of the eyes and bloody vomit[6]. Bleeding into the skin may make petechiae, purpura, ecchymoses and hematomas (particularly around needle infusion locales). Sorts of bleeding known to happen with Ebola infection sickness incorporate vomiting blood, coughing it up or blood in the stool[41]. Substantial bleeding is uncommon and is typically kept to the gastrointestinal tract. In general, the advancement of bleeding side effects regularly shows a more worse prognosis and this blood misfortune can bring about death[6]. All individuals tainted demonstrate a few manifestations of circulatory involvement, including impaired blood clotting. On the off chance that the infected individual does not recover, death because of various organ brokenness disorder happens inside 7 to 16 days (for the most part between days 8 and 9) after first manifestation[9]

Tests & Diagnosis

Before specifying it is an Ebola it should be checked for other diseases also e.g. Typhoid fever, Malaria, Cholera, Shigellosis, Leptospirosis, Hepatitis, Plague, Rickettsiosis, Relapsing fever, Meningitis, & other viral hemorrhagic fevers. If the person with Ebola virus syndrome is found then that person should be isolated & notified in public health professionals. The virus can be surely diagnosed in laboratory by using various tests within just few days after observing symptoms.

These tests are as follows-

IgM ELISA-Antigen-captureenzyme-linked immunosorbentassay(ELISA) testing.[8][9]

Polymerase Chain Reaction (PCR),[12]

Virus isolation.

At post recovery stage of disease, the diagnostic test available is-

Ig M &Ig G antibodies.

It can also be diagnosed by-PCR[12], Immunohistochemistry testing , virus isolation.

Risk Factor

Risk factor for Ebola is very low, but higher risk can be obtained when one can come in contact with infected person. Medical or personal care is provided without the use of any protective gear such as gloves or surgical masks.[10]

Treatment

Starting today, there is no authorized immunization accessible to battle the Ebola infection[17]. There are numerous antibodies that are presently being tried, yet none of them are accessible for clinical utilization right now. The treatment for Ebola starting today just includes escalated strong mind and incorporates:

- Balancing the electrolytes and liquids of a infected patient.[16]
- Maintaining their pulse and oxygen status
- Treating a patient for any confounding diseases

While there are exploratory medications that have been tried and demonstrated successful in creature models, none of them have been utilized within people. Extremely sick patients oblige serious strong consideration. They are much of the time dried out and need intravenous liquids or oral rehydration with results that contain electrolytes. There is at present no particular treatment to cure the sickness. A few patients will recuperate with the proper therapeutic forethought. To help control further spread of the infection, individuals that are suspected or affirmed to have the ailment ought to be separated from different patients and treated by wellbeing laborers utilizing

strict disease control safety measures. In the United States, in the setting of a phase I clinical trial, the FDA's creature adequacy standard might be utilized to exhibit sensible wellbeing to acquire consent to treat individuals who are tainted with Ebola. The creature viability tenet exists, on the grounds that the ordinary way for testing the security and adequacy of medications is unrealistic for maladies brought about by perilous pathogens or poisons. The FDA has permitted two medications, Zmapp and a RNA interference medication called TKM-Ebola, [18] to be utilized as a part of individuals tainted with Ebola under these projects amid the 2014 episode. As of Aug 14, 2014 there is no FDA endorsed prescriptions or immunizations to treat or avoid Ebola and encourage individuals to watch out for false products. The inaccessibility of trial medications in the most influenced areas amid the 2014 episode impelled debate, with some calling for exploratory medications to be made all the more broadly accessible in Africa on a humane premise, and others cautioning that making dubious test medications generally accessible would be exploitative, particularly in light of past experimentation directed in creating nations by Western medication organizations. On 12 August the WHO discharged an announcement that the utilization of not yet demonstrated medicines is moral in specific circumstances in an exertion to treat or keep the illness. In July 2014, a test medication, Zmapp,[42] was initially tried on people. It was managed to two Americans who had been infected with Ebola. Both individuals seemed to have had positive result[43, 44]. Zmapp was additionally managed to a third individual with Ebola, a 75 year old Spanish priest, who died [45] and three Liberian wellbeing specialists who demonstrated change. Favipiravir appears as though it might be valuable in a mouse model of the ailment[6]. Estrogen receptor medications used to treat infertility and breast malignancy (clomiphene and toremifene) hinder the advancement of Ebola infection in infected mice[46]. Ninety percent of the mice treated with clomiphene and fifty percent of those treated with toremifene survived the tests[46]. A 2014 study found that Amiodarone, an ion channel blocker utilized within the treatment of heart arrhythmias, hinders the entrance of ebola infection into cells *in vitro*[47]. Given their oral accessibility and history of human utilize, these medications would be competitors for treating Ebola infection contamination in remote topographical areas, either on their own or together with Antibodies. Specialists taking a gander at slides of cultures of cells that make monoclonal antibodies. These are developed in a lab and the scientists are dissecting the items to choose the most guaranteeing of them. Amid an episode 1999 in the Democratic Republic of the Congo, seven of eight Ebola patients who got blood transfusions from people who had at one time survived the infection survived themselves. Notwithstanding, this potential treatment is considered controversial. Intravenous antibodies seem, by all accounts, to be defensive in non-human primates

who have been laid open to extensive measurements of Ebola. Other guaranteeing medications depend on antisense engineering. Both little meddling RNAs (siRNAs) and phosphorodiamidate morpholino oligomers (PMOs) focusing on the Zaire Ebola infection (ZEBOV) RNA polymerase L protein could avoid malady in nonhuman primates[48, 49]. TKM-Ebola is a little meddling RNA compound, presently tried in a phase I clinical trial in people[18, 50]

Vaccine Development

A few creature models have been produced to study the pathogenesis of Ebola infection contamination and to evaluate the viability of different immunization approaches. Guinea pigs and nonhuman primates speak to the essential creature models for antibody advancement in light of the fact that the movement and pathogenesis most nearly take after those of the human ailment[52, 58, 59]. A murine model was later created by serial section of infection in mice[51]. In spite of the fact that the model permits the utilization of knockout and innate strains to assess hereditary determinants of disease. It is viewed as less predictive of human sickness on the grounds that it depends on a serially passaged, attenuated infection. While indications and time course of infection in guinea pigs parallel those in people, nonhuman primate disease is viewed as the most predictive and valuable for immunization advancement[53]. Live attenuated infections and recombinant proteins have been utilized effectively within a mixture of antibodies, however the wellbeing and immunogenicity of quality based immunizations have demonstrated progressively alluring. Among the quality based methodologies, exposed plasmid DNA has been utilized effectively as a part of creature models to steer the blend of immunogens inside the host cells and has demonstrated accommodating in an assortment of irresistible infections[54, 60]. Hereditary vaccination with plasmid DNA was created in the guinea pig and was the first fruitful antibody for Ebola infection[58]. In this model, NP evoked a fundamentally humoral reaction and was less viable, while sGp and GP inspired T-cell proliferative and cytotoxic reactions and a humoral reaction. Security against deadly test was presented by each of these immunogens when creatures were contaminated inside 1 month of the last vaccination, yet just GP or sGp gave long-lasting protection. The level of assurance connected with immune response titer and antigen-particular T-cell reactions. Resulting investigations of NP and GP plasmids presented defensive insusceptibility in mice,[61] however it is unverifiable whether the constricted murine infection is more delicate to balance than the wild-sort infection. In this manner, the relative strength of NP, or its necessity as an immunogen for giving long haul assurance, stays dubious. While DNA antibodies have been exceedingly viable in rodents, their viability in nonhuman primates or people has been less great. Preparing boosting inoculation conventions that utilization DNA vaccination emulated by boosting with poxvirus

vectors convey the qualities for pathogen proteins have yielded drastically improved safe reactions in creature studies, with 30-fold or more prominent increments in neutralizer titer from the supporter[55]. An alternate preparing boosting technique utilizing replication-imperfect adenovirus for an Ebola infection antibody was tried in cynomolgus macaques[56]. This study showed the prevalent immunologic adequacy of this preparing boosting combo for both cell and humoral reactions. These creatures showed complete insusceptible assurance against a deadly test of infection, giving the first exhibit of an Ebola infection antibody approach that ensures primates against contamination. As of late, a quickened inoculation has been produced that gives assurance against a deadly infection challenge in nonhuman primates after a solitary vaccination[57]. In the event that this immunization lives up to expectations comparatively in people, it might be valuable in the regulation of intense episodes by ring inoculation. In outline, an understanding of the systems underlying Ebola infection instigated cytopathic impacts has encouraged the methodology of antibody and antiviral treatment improvement, which has thus given new data about pathogenesis and the invulnerable reaction. Ebola infection does not display the high level of variability that other concealed infections may utilize to avoid host invulnerability, however Ebola infection GP adjusts target-cell work and represents a novel technique for resistant avoidance that may have emerged through the development of Ebola infection with its common host. The cytotoxic impacts of GP on macrophage and endothelial cell capacity upset incendiary cell capacity and the trustworthiness of the vasculature. Also, by modifying the cell surface interpretation of attachment proteins and resistant distinguishment atoms, Ebola infection may disturb forms discriminating to invulnerable actuation and cytolytic-T-cell capacity. These phenomena likely record for the dysregulation of the provocative reaction and the vascular brokenness normal for deadly Ebola infection disease, giving a basis to concentrating on GP as a focus for a safeguard immunization and giving prompt other clinical mediations. Trying the vaccine on a strain of Ebola that more resembles one that infects humans is the next step[15]. The Russian scientists who works in Saint Peter Burg's Research institute of Influenza has invented the vaccine on Ebola virus and it is being used in African patients for the treatment of Ebola. They have proved that this vaccine can cure the Ebola virus and can be used in the future and there are no side effects of that vaccine.

Precaution

It is still moderately obscure how individuals are continuously infected with the Ebola infection. Consequently, the preventive measures includes are still misty. There are a couple of essential preventive measures that may help, for example,

• Wearing protective clothing, for example, gloves, masks, goggles and outfits for health awareness experts.[8]

• Using infection control measures, for example, routine use of disinfectant and complete equipment sterilization

• Isolating Ebola patients from contact with unprotected persons.[10]

Bringing issues to light of the danger components and measures individuals can take to secure themselves are the main approaches to lessen sickness and deaths.

Ways to prevent infection and transmission:

While beginning instances of Ebola infection sickness are shrunk by taking care of contaminated creatures or corpses, optional cases happen by immediate contact with the body fluids of a sick individual, either through risky case administration or hazardous internment polishes. During this episode, the greater part of the illness has spread through human-to-human transmission. A few steps could be taken to help in avoiding contamination and restricting or ceasing transmission.

* Understand the way of the infection, how it is transmitted, and how to keep it from spreading further.

* Listen to and take after mandates issued by your nation's individual Ministry of Health.

* If you think somebody near you or in your group of having Ebola infection ailment, energize and help them in looking for suitable therapeutic treatment in a care facility.

* If you decide to tend to a sick individual in your home, inform open wellbeing authorities of your aims so they can prepare you and give fitting gloves and personal protective equipment (PPE), and also instructions as a reminder on how to properly care for the patient, secure yourself and your family, and appropriately discard the PPE after utilization.

* When going to patients in the clinic or looking after somebody at home, hand washing with cleanser and water is proposed in the wake of touching a patient, being in contact with their body fluids, or touching his/her surroundings.[6]

* People who have died from Ebola ought to just be taken care of utilizing suitable defensive supplies and ought to be covered promptly.

Also, people ought to diminish contact with high-hazard infected animals (i.e. foods grown from the ground bats, monkeys or chimps) in the influenced rainforest territories. In the event that you think an animal is infected, don't handle it. animal items (blood and meat) ought to be completely cooked before consuming.

Wellbeing laborers treating patients with suspected or affirmed sickness are at higher danger of contamination than different gatherings.

* Notwithstanding standard human services safety measures, wellbeing laborers ought to strictly apply prescribed contamination control measures to keep away from introduction to tainted blood fluids, or debased situations or articles –, for example, an understanding's ruined cloth or utilized needles.[10]

* They ought to utilize individual security gear, for example, individual outfits, gloves, masks and goggles or face shield.[10]

* They ought not to reuse defensive gear or attire unless they have been appropriately sanitized.[6]

* They ought to change gloves between tending to every patient associated with having Ebola.

* Invasive methods that can uncover therapeutic specialists, attendants and others to disease ought to be done under strict, safe conditions.

* Infected patients ought to be kept separate from different patients and healthy individuals, however much as could be expected.[10]

CONCLUSION

Ebola virus provides a better understanding of life cycle, pathophysiology, sign & symptoms, test &diagnosis, risk factor, treatment, precaution & starting point for searching a new chemical entities (NCE) to fight against this virus. Ebola virus disease are considered major epidemics which are threatening billions of people in the world today with no effective remedies available to treat patient but still GSK Glaxo smith Kline ready to launch advanced vaccine to treat Ebola virus most probably for use in this year. So wide era is available for researcher to develop new chemical entities to fight against the virus.

REFERENCES

1. "Ebola virus disease Fact sheet N°103". World Health Organization. 2014-03-01. Retrieved 2014-04-12.
2. "Ebola Viral Disease Outbreak — West Africa, 2014". CDC. 2014-06-27. Retrieved 2014-06-26.
3. "CDC urges all US residents to avoid nonessential travel to Liberia, Guinea and Sierra Leone because of an unprecedented outbreak of Ebola.". CDC. 2014-07-31. Retrieved 2014-08-02.
4. "Outbreak of Ebola in Guinea, Liberia and Sierra Leone". CDC. 2014-08-04. Retrieved 2014-08-05.
5. "Ebola Hemorrhagic Fever: Signs and Symptoms". United States Centers for Disease Control and Prevention.

6. Gatherer D (2014). "The 2014 Ebola virus disease outbreak in West Africa". J. Gen. Virol.**95** (Pt 8): 1619–1624. doi:10.1099/vir.0.067199-0. PMID 24795448.
7. "Ebola Hemorrhagic Fever Signs and Symptoms". CDC. 2014-01-28. Retrieved 2014-08-02.
8. "Ebola virus disease". Fact sheet N°103. World Health Organization. 2014-04-01.
9. Simpson DIH (1977). "Marburg and Ebola virus infections: a guide for their diagnosis, management, and control" (PDF). WHO Offset Publication No. 36. p. 10f.
10. "Ebola Hemorrhagic Fever Prevention". CDC. July 31, 2014. Retrieved 2014-08-02.
11. Sullivan N, Yang ZY, Nabel GJ (2003). "Ebola Virus Pathogenesis: Implications for Vaccines and Therapies" (Free full text). Journal of Virology**77** (18): 9733–9737. doi:10.1128/JVI.77.18.9733-9737.2003. PMC 224575. PMID 12941881.
12. "Ebola Hemorrhagic Fever Diagnosis". CDC. January 28, 2014. Retrieved 2014-08-03.
13. Suzuki Y, Gojobori T (1997). "The origin and evolution of Ebola and Marburg viruses". Molecular Biology and Evolution**14** (8): 800–6. doi:10.1093/oxfordjournals.molbev.a025820. PMID 9254917.
14. "Viral Hemorrhagic Fever". San Francisco Department of Public Health. Communicable Disease Control and Prevention. Retrieved 2014-08-17.
15. "Viral Hemorrhagic Fever: Ribavirin Therepy". San Francisco Department of Public Health. Infectious Disease Emergencies. Retrieved 2014-08-17.
16. Bausch DG, Feldmann H, Geisbert TW, Bray M, Sprecher AG, Boumandouki P, Rollin PE, Roth C (2007). "Outbreaks of Filovirus Hemorrhagic Fever: Time to Refocus on the Patient". The Journal of Infectious Diseases**196**: S136–S141. doi:10.1086/520542. PMID 17940941.
17. Briggs H. "BBC News - Ebola: Experimental drugs and vaccines". BBC News. Retrieved 2014-08-08.
18. Pollack, Andrew (7 August 2014) Second Drug Is Allowed for Treatment of Ebola The New York Times, Retrieved 2014-08-08
19. Hewlett, Barry; Hewlett, Bonnie (2007). Ebola, Culture and Politics: The Anthropology of an Emerging Disease. Cengage Learning. p. 103. Retrieved 2014-07-31.
20. "Ebola haemorrhagic fever in Zaire, 1976". Bull. World Health Organ.**56** (2): 271–93. 1978. PMC 2395567. PMID 307456.
21. "Ebola virus disease". Retrieved 2014-08-15.
22. "Mystery DR Congo fever kills 100". BBC News. 2007-08-31. Retrieved 2008-02-25.
23. Formenty P, Libama F, Epelboin A, Allarangar Y, Leroy E, Moudzeo H, Tarangonia P, Molamou A, Lenzi M, Ait-Ikhlef K, Hewlett B, Roth C, Grein T (2003). "[Outbreak of Ebola

hemorrhagic fever in the Republic of the Congo, 2003: a new strategy?]". Med Trop (Mars) (in French) **63** (3): 291–5. PMID 14579469.

24. "Ebola Outbreak Confirmed in Congo". NewScientist.com. 2007-09-11. Retrieved 2008-02-25.
25. Ebola outbreak in Congo. CDC news. 2007-09-12. Retrieved 2009-05-31.
26. "Uganda: Deadly Ebola Outbreak Confirmed – UN". UN News Service. 2007-11-30. Retrieved 2008-02-25.
27. "DRC Confirms Ebola Outbreak". Voanews.com. Retrieved 2013-04-15.
28. "WHO | Ebola outbreak in Democratic Republic of Congo". Who.int. 2012-08-17. Retrieved 2013-04-15.
29. "WHO | Ebola outbreak in Democratic Republic of Congo – update". Who.int. 2012-08-21. Retrieved 2013-04-15.
30. Castillo M (2012). Ebola virus claims 31 lives in Democratic Republic of the Congo. United States: CBS News. Retrieved 14 September 2012.
31. "Guidelines for Evaluation of US Patients Suspected of Having Ebola Virus Disease". CDC. 2014-08-01. Retrieved 2014-08-05.
32. Grady, Denise; Sheri Fink (2014-08-09). "Tracing Ebola's Breakout to an African 2-Year-Old". The New York Times. ISSN 0362-4331. Retrieved 2014-08-10.
33. "Outbreak of Ebola in Guinea and Liberia". Centers for Disease Control and Prevention. Retrieved 2014-04-13.
34. World Health Organization (2014-04-07). "Ebola virus disease, West Africa (Situation as of 7 April 2014) - Guinea". ReliefWeb.
35. "Ebola virus disease, West Africa". World Health Organization Regional Office for Africa. 2014-07-31.
36. "WHO raises global alarm over Ebola outbreak". CBS. Retrieved 2014-08-02.
37. "Ebola epidemic in West Africa declared a health emergency". Big News Network.com. Retrieved 2014-08-02.
38. "Using a Tactic Unseen in a Century, Countries Cordon Off Ebola-Racked Areas". New York Times. Retrieved 2014-08-13.
39. "In Liberia's Ebola-Stricken Villages, Residents Face 'Stark' Choices". n Liberia's Ebola-Stricken Villages, Residents Face 'Stark' Choices. Common Dreams. 18 August 1014. Retrieved 20 August 2014.
40. "Whole of West Point area at risk after Ebola quarantine centre attacked and looted". Liberia News.Net. 2014-08-17. Retrieved 2014-08-17.

41. "FDA warns consumers about fraudulent Ebola treatment products". Retrieved 20 August 2014.
42. "In Ebola Outbreak, Who Should Get Experimental Drug?". The New York Times. 2014-08-08.
43. "Experimental drug likely saved Ebola patients". CNN. 2014-08-04.
44. "Mystery Ebola virus serum manufactured by San Diego firm". Los Angeles Times. 2014-08-04.
45. "Spanish Priest Dies from Ebola Despite Z-Mapp Treatment". TIME.
46. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG (2013). "FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection". Sci Transl Med**5** (190): 190ra79. doi:10.1126/scitranslmed.3005471. PMC 3955358. PMID 23785035. Lay summary – Healthline Networks, Inc.
47. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, Pöhlmann S, Vondran FW, David S, Manns MP, Ciesek S, von Hahn T (2014). "The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry". J. Antimicrob. Chemother.**69** (8): 2123–31. doi:10.1093/jac/dku091. PMID 24710028.
48. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I (2010). "Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study". The Lancet**375** (9729): 1896–1905. doi:10.1016/S0140-6736(10)60357-1. PMID 20511019.
49. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S (2010). "Advanced antisense therapies for postexposure protection against lethal filovirus infections". Nature Medicine**16** (9): 991–994. doi:10.1038/nm.2202. PMID 20729866.
50. Helen Branswell (August 3, 2014). "Nancy Writebol, U.S. missionary, didn't get TKM-Ebola drug, Tekmira says". The Canadian Press.
51. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:651-661.
52. Connolly, B. M., K. E. Steele, K. J. Davis, T. W. Geisbert, W. M. Kell, N. K. Jaax, and P. B. Jahrling. 1999. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179:S203-S217.

53. Geisbert, T. W., P. Pushko, K. Anderson, J. Smith, K. J. Davis, and P. B. Jahrling. 2002. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8:503-507.
54. Donnelly, J. J., J. B. Ulmer, J. W. Shiver, and M. A. Liu. 1997. DNA vaccines. Annu. Rev. Immunol. 15:617-648.
55. Schneider, J., S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. Hill. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
56. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z.-Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
57. Sullivan, N. J., T. W. Geisbert, L. Xu, Z.-Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for ebola virus hemorrhagic fever in non-human primates. Nature 424:681-684.
58. Wyers, M., P. Formenty, Y. Cherel, L. Guigand, B. Fernandez, C. Boesch, and B. Le Guenno. 1999. Histopathological and immunohistochemical studies of lesions associated with Ebola virus in a naturally infected chimpanzee. J. Infect. Dis. 179:S54-S59
59. Wilson, J. A., M. Hevey, R. Bakken, S. Guest, M. Bray, A. L. Schmaljohn, and M. K. Hart. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664-1666.
60. Tighe, H., M. Corr, M. Roman, and E. Raz. 1998. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19:89-97.
61. Vanderzanden, L., M. Bray, D. Fuller, T. Roberts, D. Custer, and K. Spik. 1998. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 246**:**134-144.